News

28/01/2008
IPSOGEN licenses the Breast Cancer Genomic Grade™

21/01/2008
Ipsogen reports recommendation of JAK2V617F mutation screening in WHO 2008 criteria

03/12/2007
IPSOGEN and AstraZeneca start study on JAK2 cancer biomarker

26/11/2007
A multi-center evaluation of WT1 assay in AML patients presented at the 49th ASH Annual Meeting

20/11/2007
IPSOGEN launches the first quantitative JAK2 V617F mutation kit

29/10/2007
Ipsogen announces ISO :13485 certification for IVD

24/10/2007
Ipsogen launches 10 new references to its product portfolio

17/09/2007
IPSOGEN in-licenses NPM1 mutations' technology from XENOMICS

10/09/2007
Ipsogen grants Labcorp a license for JAK2 testing in the US

04/09/2007
IPSOGEN and DNAVision enter in Agreement to offer In Vitro Diagnostic Tests for Breast Cancer.

28/08/2007
Affymetrix and IPSOGEN Collaborate to Develop and Market In-Vitro Diagnostic Cancer Tests.

14/08/2007
Ipsogen grants an exclusive licence to Warnex for JAK2 testing in CANADA.

01/08/2007
Ipsogen opens new US offices in New Haven, CT.

25/05/2007
The new JAK2 MutaScreen™ Kit & Reference Scale for the detection and estimation of % JAK2 V617F mutated allele is now available. This kit will improve disease management of MPD patients.

24/05/2007
IPSOGEN is part of COBRED, a breast & colon cancer biomarker European project.

07/05/2007
Connecticut Innovations Completes Investment of $500,000 in Ipsogen Inc.

13/12/2006
Ipsogen and anti cancer centres to initiate a prospective clinical trial for use of a genomic signature for managing chemotherapeutic options in breast cancer.

06/12/2006
Ipsogen in the press :
http://www.biotribune.com/innovation/index.php?Mode=Detail&idInnov=67
Biotribune dated 06/12/2006

18/10/2006
Ipsogen, the leader in molecular diagnostic of leukemia, is pleased to announce the immediate availability of its new JAK2 MutaScreenT Kit(ref#MSPP-01) for V617F mutation detection in myeloproliferative disorders.

20/04/2006
Ipsogen launches a new BCR-ABL Mbcr Positive Control to check the quality of your RQ-PCR assays and Mbcr Mega Kit (CE marked) for laboratories with high volume testing.

31/03/2006
Ipsogen licenses JAK2 mutation test to improve the diagnosis of blood-based disorders.

27/02/2006
Ipsogen presents its latest breast cancer biomarker results at EBCC5.

21/02/2006
In order to improve the disease management of AML patients, Ipsogen announces the launch of its ProfileQuant® Kit BAALC for detection and quantification of the BAALC gene transcript, a candidate prognostic biomarker in AML patients .

23/11/2005
Ipsogen presents breast cancer biomarker results at the European Cancer Conference ECCO 13

12/09/2005
Genaissance Pharmaceuticals and Ipsogen announce cancer biomarker research agreements

08/09/2005
Ipsogen announces the launch of its IpsoQuantT software , a complete data management solution for the molecular follow-up of Leukemia patients.

24/06/2005
Ipsogen receives 2005 "Price for Innovation"

13/05/2005
Ipsogen announces the launch of its ProfileQuant® quantitative molecular kits for a range of solid tumor markers: ESR1, ERBB2, GATA3 and SCUBE2.

30/03/2005
Ipsogen to present breast cancer program results at the upcoming AACR annual meeting.

16/03/2005
Ipsogen announces the recent opening of additional offices in the USA, further expanding its ability to deliver a growing range of oncodiagnostic products worldwide.

03/03/2005
IPSOGEN has annouced that it has been formally accepted as a participant of the European LeukemiaNet at the 2nd symposium of the European LeukemiaNet in Heidelberg, Germany.